Loading...
Loading...
In a report published Friday, Jefferies reiterated its Buy rating on Ventas
VTR, and raised its price target from $72.00 to $78.00.
Jefferies noted, “Despite the ~13% return since October, we still see long-term value in VTR, given: 1) a high quality portfolio heavily weighted towards private-pay assets, 2) a strong balance sheet with an attractive cost of capital, and 3) a seasoned management team with significant deal experience, positioning VTR for solid long-term growth. As a result, VTR remains one of our top healthcare REIT picks. Raising PT to $78 and maintain our Buy rating.”
Ventas closed on Thursday at $70.78.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in